Caxton Associates LLP Verona Pharma PLC Transaction History
Caxton Associates LLP
- $3.94 Trillion
- Q2 2025
A detailed history of Caxton Associates LLP transactions in Verona Pharma PLC stock. As of the latest transaction made, Caxton Associates LLP holds 35,716 shares of VRNA stock, worth $3.81 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
35,716Holding current value
$3.81 Million% of portfolio
0.09%Shares
1 transactions
Others Institutions Holding VRNA
# of Institutions
322Shares Held
76.8MCall Options Held
977KPut Options Held
3.12M-
Janus Henderson Group PLC London, X06.13MShares$655 Million0.3% of portfolio
-
Perceptive Advisors LLC New York, NY5.51MShares$588 Million22.87% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y94.13MShares$441 Million16.48% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA3.38MShares$361 Million16.88% of portfolio
-
Rtw Investments, LP New York, NY3.05MShares$326 Million4.43% of portfolio
About Verona Pharma plc
- Ticker VRNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,954,200
- Market Cap $6.51B
- Description
- Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodi...